Small-cell carcinoma

China Nivolumab Market Investigation Report 2021-2025: A Human IgG4 Monoclonal Antibody that Blocks PD-1 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 1, 2021
Health, Pharmaceutical, Drugs, Clinical medicine, Health sciences, Lung cancer, Bristol-Myers Squibb, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Nivolumab, Head and neck cancer, Non-small-cell lung carcinoma, Small-cell carcinoma

The "Investigation Report on China's Nivolumab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Nivolumab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • According to this market research, after Nivolumab entered the Chinese market, the sales value of Nivolumab in China increased from CNY9.9 million in 2018 to CNY 43.1 million in 2020.
  • Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1, mainly used to treat non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, advanced renal cell carcinoma, and head and neck squamous cell carcinoma.
  • 2 Sales of Nivolumab in China, 2018-2020
    2.3 Sales of Nivolumab by Dosage Form in China, 2018-2020
    3 Analysis of Major Nivolumab Manufacturers in China, 2018-2020
    4 Prices of Nivolumab for Different Manufacturers in China, 2020-2021
    5 Prospect of Chinese Nivolumab drug Market, 2021-2025

New Research Shows EarlySign's AI Model More Accurate for Early Diagnosis of Non-small Cell Lung Cancer

Retrieved on: 
Wednesday, May 26, 2021
Lung cancer, Cancer, Health, Non-small-cell lung carcinoma, Lung cancer, Small-cell carcinoma, Branches of biology

TEL AVIV, Israel, May 26, 2021 /PRNewswire/ -- Medial EarlySign (earlysign.com), a pioneering company developing AI-based clinical data solutions for early detection and prevention of high-burden diseases, announced today the publication of new research impacting the early diagnosis of non-small cell lung cancer (NSCLC).

Key Points: 
  • TEL AVIV, Israel, May 26, 2021 /PRNewswire/ -- Medial EarlySign (earlysign.com), a pioneering company developing AI-based clinical data solutions for early detection and prevention of high-burden diseases, announced today the publication of new research impacting the early diagnosis of non-small cell lung cancer (NSCLC).
  • The peer-reviewed retrospective data study, Machine Learning for Early Lung Cancer Identification Using Routine Clinical and Laboratory Data , was published in the American Thoracic Journal, "American Journal of Respiratory and Critical Care Medicine."
  • With further validation and refinement, this model has the potential to help prevent lung cancer deaths through earlier diagnosis.
  • The machine learning models from EarlySign can help advance lung cancer identification by nine to twelve months which can lead to earlier diagnosis and treatment, when it matters the most."

First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker

Retrieved on: 
Wednesday, May 26, 2021
Branches of biology, Clinical medicine, Lung cancer, Biology, Biomarkers, Breakthrough therapy, Orphan drugs, Monoclonal antibodies, Non-small-cell lung carcinoma, Small-cell carcinoma, Treatment of lung cancer, Atezolizumab

The BEACON-Lung study aims to evaluate biomarkers to predict overall survival and early progression outcomes in treatment-nave advanced stage non-small cell lung cancer (NSCLC) patients with high PD-L1 expression.

Key Points: 
  • The BEACON-Lung study aims to evaluate biomarkers to predict overall survival and early progression outcomes in treatment-nave advanced stage non-small cell lung cancer (NSCLC) patients with high PD-L1 expression.
  • "The BEACON-Lung study furthers ALCMI's mission to work with partners like Biodesix to overcome barriers to treatment in lung cancer," said Tony Addario, chair and CEO of ALCMI.
  • The study, being conducted through ALCMI's prestigious research consortium of leading US academic centers, launched early this year.
  • BEACON-Lung is a study that aims address this current gap in biomarker development and treatment selection for advanced non-small cell lung cancer."

Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

Retrieved on: 
Monday, May 24, 2021
Lung cancer, Clinical medicine, Medicine, Cancer, Non-small-cell lung carcinoma, Brain metastasis, Small-cell carcinoma, Treatment of lung cancer, Targeted therapy of lung cancer

Patients with brain metastasis resulting from non-small cell lung cancer generally have few treatment options and poor outcomes.

Key Points: 
  • Patients with brain metastasis resulting from non-small cell lung cancer generally have few treatment options and poor outcomes.
  • We look forward to generating data from use of Tumor Treating Fields in this and several other major cancer types as soon as possible.
  • TTFields are administered to patients concomitantly with the best standard of care treatments that would normally be used to treat lung cancer.
  • Lung cancer consists of NSCLC in approximately 85% of cases and small cell lung cancer (SCLC) in approximately 15% of cases.

BeyondSpring Presents Phase 1 Data on the Anti-Cancer Effect of Plinabulin in Combination with Checkpoint Inhibitors in SCLC at the American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Monday, May 24, 2021
Clinical medicine, Cancer treatments, Drugs, Lung cancer, Bristol-Myers Squibb, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Ipilimumab, Nivolumab, Small-cell carcinoma, Checkpoint inhibitor

The poster, titled A Phase I Trial of Plinabulin in Combination with Nivolumab and Ipilimumab in Patients with Recurrent Small Cell Lung Cancer (SCLC), will be presented at 9 a.m.

Key Points: 
  • The poster, titled A Phase I Trial of Plinabulin in Combination with Nivolumab and Ipilimumab in Patients with Recurrent Small Cell Lung Cancer (SCLC), will be presented at 9 a.m.
  • ORR was 50% for the six patients receiving the triple IO combination as second line therapy after platinum.
  • SCLC still represents an area of tremendous unmet medical need.This study supports the hypothesisthat theaddition ofplinabulin toanivolumab+ipilimumabregimen could increaseresponse ratesin 2nd/3rd line SCLC.
  • The study is small,but some patients who previously developed resistance to checkpoint inhibitors had durable responses and large tumor reduction.

Global Lung Cancer Epidemiology and Patient Flow Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 24, 2021
Pharmaceutical, Health, Oncology, Lung cancer, Health effects of tobacco, Carcinogenesis, Epidemiology of cancer, Cancer, Epidemiology, Articles, Health, Small-cell carcinoma, Treatment of lung cancer

The "Global Lung Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Lung Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Lung Cancer Epidemiology and Patient Flow Analysis - 2021, provides Lung Cancer epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Lung Cancer patients, history of the disease at the population level (Lung Cancer prevalence, Lung Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Lung Cancer patients by age group, gender
    The data from this research will help executives:
    Establish basis for Lung Cancer market sizing, assessing market potential, and developing drug forecast models
    Identify Lung Cancer patients segments through age groups, gender, and disease sub-types
    Evaluate Lung Cancer market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005609/en/

Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Retrieved on: 
Friday, May 21, 2021
FDA, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, Lung cancer, Clinical medicine, Medicine, Branches of biology, Oncology, Non-small-cell lung carcinoma, Epidermal growth factor receptor, Liquid biopsy, Cancer, Small-cell carcinoma

The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes, and lower healthcare costs across all stages of the cancer care continuum.

Key Points: 
  • The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes, and lower healthcare costs across all stages of the cancer care continuum.
  • Guardant Health has commercially launched liquid biopsy-based Guardant360\xc2\xae, Guardant360 CDx, and GuardantOMNI\xc2\xae tests for advanced stage cancer patients, and Guardant Reveal\xe2\x84\xa2 test for early-stage cancer patients.
  • The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.
  • 2016;7(48):78985-78993.\nRemon J, Hendriks LEL, Cardona AF, Besse B. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.

FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

Retrieved on: 
Friday, May 21, 2021
Lung cancer, Organic compounds, Chemical compounds, Cancer, Non-small-cell lung carcinoma, Epidermal growth factor receptor, Small-cell carcinoma, Afatinib, Gefitinib

"With today\'s approval, for the first time, patients with non-small cell lung cancer with EGFR exon 20 insertion mutations will have a targeted treatment option.

Key Points: 
  • "With today\'s approval, for the first time, patients with non-small cell lung cancer with EGFR exon 20 insertion mutations will have a targeted treatment option.
  • "\nLung cancer is the most common cancer type and the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer accounting for 80% to 85% of all lung cancers, according to the American Cancer Society.
  • Approximately 2% to 3% of patients with non-small cell lung cancer will have EGFR exon 20 insertion mutations, which are a group of mutations on a protein that causes rapid cell growth, and consequently, helps cancer spread.
  • Rybrevant should be withheld if patients develop symptoms of interstitial lung disease and permanently discontinued if interstitial lung disease is confirmed.

Global Small Cell Lung Cancer Markets, Epidemiology and Patient Flow Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021
Health, Oncology, Cancer, Lung cancer, Clinical medicine, Health, Infectious causes of cancer, Carcinogenesis, Health effects of tobacco, Carcinoma, Small-cell carcinoma, Epidemiology of cancer, Treatment of lung cancer, Head and neck cancer

b'The "Global Small Cell Lung Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2021, provides Small Cell Lung Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Small Cell Lung Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2021, provides Small Cell Lung Cancer epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Small Cell Lung Cancer patients, history of the disease at the population level (Small Cell Lung Cancer prevalence, Small Cell Lung Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nSmall Cell Lung Cancer patient flow: Small Cell Lung Cancer prevalence, diagnosed, and drug-treated patients\nDemographics: Small Cell Lung Cancer patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Small Cell Lung Cancer market sizing, assessing market potential, and developing drug forecast models\nIdentify Small Cell Lung Cancer patients segments through age groups, gender, and disease sub-types\nEvaluate Small Cell Lung Cancer market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210521005349/en/\n'

Global Non-Small Cell Lung Cancer Markets, Epidemiology and Patient Flow Report 2020-2021 & 2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021
Health, Oncology, Lung cancer, Cancer, Clinical medicine, Health, Small-cell carcinoma, Epidemiology of cancer, Non-small-cell lung carcinoma, Treatment of lung cancer, Head and neck cancer

b'The "Global Non-Small Cell Lung Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Non-Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2021, provides Non-Small Cell Lung Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Non-Small Cell Lung Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Non-Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2021, provides Non-Small Cell Lung Cancer epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Non-Small Cell Lung Cancer patients, history of the disease at the population level (Non-Small Cell Lung Cancer prevalence, Non-Small Cell Lung Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nNon-Small Cell Lung Cancer patient flow: Non-Small Cell Lung Cancer prevalence, diagnosed, and drug-treated patients\nDemographics: Non-Small Cell Lung Cancer patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Non-Small Cell Lung Cancer market sizing, assessing market potential, and developing drug forecast models\nIdentify Non-Small Cell Lung Cancer patients segments through age groups, gender, and disease sub-types\nEvaluate Non-Small Cell Lung Cancer market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210521005336/en/\n'